Squarepoint Ops LLC Cti Biopharma Corp Transaction History

Squarepoint Ops LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.2 - $6.01 $315,067 - $450,846	75,016 Added 234.15%	107,053 $449,000
Q4 2022 Feb 14, 2023	BUY	$4.45 - $6.17 $142,564 - $197,668	32,037 New	32,037 $192,000
Q2 2022 Aug 15, 2022	SELL	$3.55 - $6.27 $607,621 - $1.07 Million	-171,161 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.9 - $5.23 $325,205 - $895,172	171,161 New	171,161 $799,000
Q3 2021 Nov 15, 2021	SELL	$2.25 - $3.18 $162,731 - $229,993	-72,325 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$2.16 - $2.62 $270,401 - $327,987	-125,186 Reduced 63.38%	72,325 $181,000
Q1 2021 May 17, 2021	BUY	$2.68 - $3.8 $529,329 - $750,541	197,511 New	197,511 $575,000
Q4 2019 Feb 14, 2020	SELL	$0.72 - $1.64 $64,244 - $146,333	-89,228 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$0.64 - $0.92 $33,793 - $48,578	52,803 Added 144.96%	89,228 $75,000
Q2 2019 Aug 14, 2019	BUY	$0.8 - $1.03 $29,140 - $37,517	36,425 New	36,425 $31,000
Q3 2018 Nov 14, 2018	SELL	$1.72 - $5.24 $22,535 - $68,654	-13,102 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$3.81 - $5.26 $49,918 - $68,916	13,102 New	13,102 $65,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.